Menu
Recruiting NCT06712420

Neoadjuvant Chemotherapy for Locally Advanced Gall Bladder Cancer : a Randomized Control Trial (NEOGB)

Phase III Interventional Gall Bladder Carcinoma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: neoadjuvant chemotherapy, curative surgery.
Who it may be relevant to
Registry conditions: Gall Bladder Carcinoma. Basic parameters: 18 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
India
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Neoadjuvant Chemotherapy Versus Upfront Surgery for Locally Advanced Resectable Gall Bladder Cancer : A Randomized Trial

Overview

to study role of chemotherapy treatment for gall bladder cancer before surgery as compared to surgery directly

Detailed description

Gallbladder cancer is a highly aggressive disease with a late presentation and poor prognosis. Complete surgical excision remains the only potentially curative treatment for early-stage gallbladder cancer.

The use and benefit of chemotherapy in gallbladder cancer before surgery , that is , in the neoadjuvant setting, is not well studied and, to our knowledge, neoadjuvant chemotherapy has not been evaluated in any randomized clinical trial.

Neoadjuvant chemotherapy aims to achieve tumor downstaging, increase the radical surgical resection rate, reduce metastases. This study will compare the effectiveness of chemotherapy before surgery in locally advanced gall bladder cancer versus upfront surgery with respect to survival and completeness of resection of disease.

Interventions

  • Drug neoadjuvant chemotherapy
    NACT group will receive gemcitabine and platinum combination. Most common regimen comprised of gemcitabine (1000 mg/ m2 intravenously over 30-60 min) on days 1 and 8, and cisplatin (75 mg/ m2 intravenously over 2 h) on day 1, every 21 days. In case of renal compromise, carboplatin was used. Response was assessed using CECT abdomen and PET scan. Chemotherapy related toxicity will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) v 5 .0. PAtients will undergo curative s
  • Procedure curative surgery
    Patient being taken up for surgical exploration will undergo staging laparoscopy followed by exploration and interaortocaval lymphnode sampling. After ruling out distant metastasis, local resectability will be reassessed and curative surgery will be performed. . Post-operative complications were recorded and graded according Clavien Dindo classification

Primary outcome measures

  • improvement in 3 year overall survival [Time frame: 3 year]
Secondary outcome measures (1)
  • post operative outcomes [Time frame: 90 days]

Eligibility criteria

Inclusion criteria

  • ECOG 0-2
  • Locally advanced resectable GBC defined as Clinical T3/4 disease or Regional LN involvement on imaging studies.
  • Post cholecystectomy GBC with residual disease on imaging, History of bile spillage during primary surgery , history of piece-meal removal of gall bladder during simple cholecystectomy, Regional LN involvement on imaging studies.

Exclusion criteria

  • Early GBC ( cT1/T2) without significant lymphadenopathy or liver infiltration on radiological imaging .
  • Locally advanced disease requiring major hepatectomy or whipple's pancreatoduodenectomy.
  • Post cholecystectomy GBC without any evidence of spillage of residual disease on radiological imaging.
  • Obstructive jaundice due to involvement of biliary tree by tumour.
  • Vascular involvement such as common hepatic artery, MPV right hepatic artery or right portal vein.
  • Any distant metastasis or isolated port site metastasis
  • Involvement of non-regional LN (e.g . Celiac LN, SMA lymph node, inter-aortocaval or left para-ortic LN).
  • Poor performance status ECOG 3 or more.
  • Pregnancy.
  • Inability or unwillingness to follow study protocol

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

India · 3 centers
  • Rajiv Gandhi Cancer Institute and Research Centre — Delhi
  • Rajiv Gandhi Cancer Institute and Research Centre — Delhi
  • Rajiv Gandhi Cancer Institute and Research Centre — Delhi

Identifiers

NCT: NCT06712420 · RGCIRC/IRB-BHR/26/2024 · RES/SCM/61/2023/89

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗